|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TISSUE-SPECIFIC STEM CELLS |
Islet and Autoimmunity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
Key Words. Adult stem cells • Bone morphogenetic protein-4 • Progenitors • Diabetes • Pancreatic islets • Proliferation • Differentiation
Correspondence: Nadya Lumelsky, Ph.D.,National Institute of Dental and Craniofacial Research/NIH, 45 Center Drive, Building 45, Room 4N 24J, Bethesda, Maryland 20892-6402, USA.Telephone: 301-594-7703;Fax: 301-480-8318;email: nadyal{at}nidcr.nih.gov
Received August 8, 2005;
accepted for publication March 20, 2006.
First published online in STEM CELLS EXPRESS March 23, 2006.
Application of pancreatic islet transplantation to treatment of diabetes is severely hampered by the inadequate islet supply. This problem could in principle be overcome by generating islet cells from adult pancreas in vitro. Although it is possible to obtain replicating cells from cultures of adult pancreas, these cells, when significantly expanded in vitro, progressively lose pancreatic-specific gene expression, including that of a "master" homeobox transcription factor Pdx1. Here we show for the first time that long-term proliferating islet progenitor-like cells (IPLCs) stably expressing high levels of Pdx1 and other genes that control early pancreatic development can be derived from cultures of adult mouse pancreas under serum-free defined culture conditions. Moreover, we show that cells derived thus can be maintained in continuous culture for at least 6 months without any substantial loss of early pancreatic phenotype. Upon growth factor withdrawal, the IPLCs organize into cell clusters and undergo endocrine differentiation of various degrees in a line-dependent manner. We propose that our experimental strategy will provide a framework for developing efficient approaches for ex vivo expansion of islet cell mass.
This article has been cited by other articles:
![]() |
V. S. Urban, J. Kiss, J. Kovacs, E. Gocza, V. Vas, E. Monostori, and F. Uher Mesenchymal Stem Cells Cooperate with Bone Marrow Cells in Therapy of Diabetes Stem Cells, January 1, 2008; 26(1): 244 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Atouf, C. H. Park, K. Pechhold, M. Ta, Y. Choi, and N. L. Lumelsky No Evidence for Mouse Pancreatic {beta}-Cell Epithelial-Mesenchymal Transition In Vitro Diabetes, March 1, 2007; 56(3): 699 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tayaramma, B. Ma, M. Rohde, and H. Mayer Chromatin-Remodeling Factors Allow Differentiation of Bone Marrow Cells into Insulin-Producing Cells Stem Cells, December 1, 2006; 24(12): 2858 - 2867. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
